FSS · Investment summary · as of 3 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
At $128.95, FSS requires a 5% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 12%.
the disagreement with the market is the durability/organicity of growth, not margin expansion; both axes clear
The value rests on an exit multiple of 21.5x, a terminal operating margin of 16% and a 8.8% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Debt-funded serial acquirer meets a municipal-budget contraction: appropriations lag recessions 1-2 years, so the counter-cyclicality that held 2020 margins can invert; simultaneous New Way integration failure impairs the ~$424m paid.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | the disagreement with the market is the durability/organicity of growth, not margin expansion; both axes clear |
| What do we forecast? | Revenue growth of 12% demonstrated; a terminal operating margin of 16%; an exit multiple of 21.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +6.7 percentage points. |
| What is it worth? | Twelve-month target $146.53, +14% from the struck price. Scenario-weighted expected return net of costs +13.6%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 29 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| quarterly 10-Q | Below 4% YoY for two consecutive quarters | At or above 4% YoY for two consecutive quarters | below 4% YoY for two consecutive quarters |
| quarterly; Q2'26 0.950, Q1'26 0.996 - watched, not breached | Consolidated book-to-bill | At or above 0.92 for two consecutive quarters | below 0.92 for two consecutive quarters |
| quarterly; Q2'26 30.4% | Gross margin | At or above 28.0% for two consecutive quarters | below 28.0% for two consecutive quarters |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
Debt-funded serial acquirer meets a municipal-budget contraction: appropriations lag recessions 1-2 years, so the counter-cyclicality that held 2020 margins can invert; simultaneous New Way integration failure impairs the ~$424m paid. Margin reverts toward the 10-year median (~11.6%), organic to ~0, multiple to the identity floor.
Estimated probability 10%, against the 22% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
trim when spot exceeds the refreshed 12-month target such that forward E[R] < 0 net of costs; re-rank against book alternatives above the 1y p75 EV/Sales (3.69x ~ $155) On approach to the $146.53 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Debt-funded serial acquirer meets a municipal-budget contraction: appropriations lag recessions 1-2 years, so the counter-cyclicality that held 2020 margins can invert; simultaneous New Way integration failure impairs the ~$424m paid. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +6.7 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: debt-funded serial acquirer meets a municipal-budget contraction: appropriations lag recessions 1-2 years, so the counter-cyclicality that held 2020 margins can invert; simultaneous New Way integration failure impairs the ~$424m paid. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $113.48, which forces an immediate review.